SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-117841
Filing Date
2021-04-15
Accepted
2021-04-15 16:41:03
Documents
12
Period of Report
2021-04-15
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d130606d8k.htm   iXBRL 8-K 20948
  Complete submission text file 0001193125-21-117841.txt   139199

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fprx-20210415.xsd EX-101.SCH 3073
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fprx-20210415_lab.xml EX-101.LAB 17374
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fprx-20210415_pre.xml EX-101.PRE 10955
5 EXTRACTED XBRL INSTANCE DOCUMENT d130606d8k_htm.xml XML 3308
Mailing Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 415-365-5600
FIVE PRIME THERAPEUTICS, INC. (Filer) CIK: 0001175505 (see all company filings)

IRS No.: 260038620 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36070 | Film No.: 21828971
SIC: 2834 Pharmaceutical Preparations